DK1900362T3 - Alfa-aminoamidderivater anvendelige ved behandlingen af addiktive forstyrrelser - Google Patents

Alfa-aminoamidderivater anvendelige ved behandlingen af addiktive forstyrrelser

Info

Publication number: DK1900362T3
Authority: DK; Denmark
Prior art keywords: treatment; alpha; addictive disorders; derivatives useful; aminoamide derivatives
Prior art date: 2004-04-22

Application number

DK07022078.5T

Other languages

English (en)

Inventor

Elena Barbanti

Emanuela Izzo

Ruggero Fariello

Patricia Salvati

Luca Benatti

Claudia Besana

Florian Thaler

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-22

Filing date

2005-04-19

Publication date

2011-05-09

2005-04-19 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2011-05-09 Application granted granted Critical

2011-05-09 Publication of DK1900362T3 publication Critical patent/DK1900362T3/da

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Addiction (AREA)
Psychiatry (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

DK07022078.5T 2004-04-22 2005-04-19 Alfa-aminoamidderivater anvendelige ved behandlingen af addiktive forstyrrelser DK1900362T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04009532A EP1588704A1 (en)	2004-04-22	2004-04-22	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP05736365A EP1737438B1 (en)	2004-04-22	2005-04-19	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome

Publications (1)

Publication Number	Publication Date
DK1900362T3 true DK1900362T3 (da)	2011-05-09

Family

ID=34924693

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK05736365T DK1737438T3 (da)	2004-04-22	2005-04-19	Alfa-aminoamidderivater til behandling af syndromet restless legs
DK07022078.5T DK1900362T3 (da)	2004-04-22	2005-04-19	Alfa-aminoamidderivater anvendelige ved behandlingen af addiktive forstyrrelser

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK05736365T DK1737438T3 (da)	2004-04-22	2005-04-19	Alfa-aminoamidderivater til behandling af syndromet restless legs

Country Status (25)

Country	Link
US (2)	US8445513B2 (da)
EP (3)	EP1588704A1 (da)
JP (1)	JP5020069B2 (da)
KR (2)	KR101195819B1 (da)
CN (1)	CN1942179B (da)
AT (2)	ATE494890T1 (da)
AU (1)	AU2005235428B2 (da)
BR (2)	BRPI0509976B8 (da)
CA (1)	CA2563674C (da)
CY (2)	CY1108494T1 (da)
DE (2)	DE602005009162D1 (da)
DK (2)	DK1737438T3 (da)
ES (2)	ES2313330T3 (da)
HR (2)	HRP20080593T3 (da)
IL (1)	IL178732A (da)
ME (2)	ME02324B (da)
MX (1)	MXPA06012163A (da)
NO (2)	NO337900B1 (da)
NZ (1)	NZ550664A (da)
PL (2)	PL1900362T3 (da)
PT (2)	PT1737438E (da)
RS (2)	RS50667B (da)
RU (1)	RU2403030C2 (da)
SI (2)	SI1900362T1 (da)
WO (1)	WO2005102300A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
SI1423168T1 (sl)	2001-09-03	2006-06-30	Newron Pharm Spa	Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
ES2339021T3 (es) *	2003-08-25	2010-05-14	Newron Pharmaceuticals S.P.A.	Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1588704A1 (en)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20080096965A1 (en) *	2004-09-10	2008-04-24	Newron Pharmaceuticals S.P.A.	(Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
JP2008519811A (ja) *	2004-11-10	2008-06-12	オリオンコーポレーション	下肢静止不能症候群の治療
EP1963280B1 (en)	2005-12-22	2015-10-28	Newron Pharmaceuticals S.p.A.	2-phenylethylamino derivatives as calcium and/or sodium channel modulators
EP2007369A4 (en) *	2006-04-03	2009-07-01	Teva Pharma	USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1870097A1 (en)	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
DK2474521T3 (da) *	2006-06-19	2016-10-31	Newron Pharm Spa	Højrene 2-[4-(3- and 2-fluorbenzyloxy)benzylamino]propanamider til anvendelse som lægemidler og farmaceutiske formuleringer dermed
GB0706630D0 (en) *	2007-04-04	2007-05-16	Glaxo Group Ltd	Novel compounds
DK2155663T3 (da)	2007-06-15	2018-01-22	Newron Pharm Spa	Substituerede 2-[2-(phenyl)ethylamino]alkanamidderivater og deres anvendelse som natrium- og/eller kalciumkanalmodulatorer
KR101593627B1 (ko)	2007-12-11	2016-02-11	뉴론 파마슈티칼즈 에스. 피. 에이.	고순도의 ２［４（３ 또는 ２플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) *	2007-12-19	2016-09-13	Newron Pharmaceuticals S.P.A.	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
EP2314569A1 (en)	2009-10-22	2011-04-27	Merck Patent GmbH	Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
NZ602648A (en)	2010-04-27	2014-10-31	Newron Pharm Spa	Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
US11278651B2 (en) *	2018-10-17	2022-03-22	Gambro Lundia Ab	Membrane and device for treating restless leg syndrome
CN114667963B (zh) *	2020-12-24	2024-04-26	中国科学院脑科学与智能技术卓越创新中心	一种非人灵长类动物药物成瘾性评估的装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en) *	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
CA1336169C (en)	1988-03-01	1995-07-04	Walther Birkmayer	Agent for treatment of parkinson's disease
IL94466A (en) *	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en)	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
EP0520325A1 (de) *	1991-06-28	1992-12-30	F.Hoffmann-La Roche & Co. Aktiengesellschaft	Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ES2211904T3 (es)	1995-05-26	2004-07-16	Pfizer Inc.	Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda.
WO1997000511A1 (de)	1995-06-17	1997-01-03	Baumann Guenter	Scheibenkörper
GB9515411D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9515412D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
DE19701619B4 (de) *	1997-01-17	2007-10-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Pramipexol zur Behandlung des restless legs syndroms
GB9727521D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Substituted 2-benzylamino-2-phenyl-acetamide compounds
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
AU761457B2 (en)	1998-01-12	2003-06-05	Deborah Wenzel	An additive composition also used as a fuel composition comprising water soluble alcohols
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
WO2001034172A2 (en) *	1999-11-05	2001-05-17	Vela Pharmaceuticals Inc.	Methods and compositions for treating reward deficiency syndrome
WO2001041763A1 (en) *	1999-12-10	2001-06-14	University Of Cincinnati	Treatment of addiction disorders
US20020019421A1 (en)	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
EP1406631A4 (en) *	2001-06-13	2005-03-23	Univ Michigan	DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
SI1511718T1 (sl) *	2002-05-29	2009-08-31	Hoffmann La Roche	Derivati n-acilaminobenzena kot selektivni inhibitorji monoaminske oksidaze b
EP1515921B1 (en)	2002-06-24	2006-03-08	Rockwool International A/S	Process and apparatus for controlling mineral wool production using a cascade rotor
US6900354B2 (en) *	2002-07-15	2005-05-31	Hoffman-La Roche Inc.	3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
JP2005060370A (ja) *	2003-07-25	2005-03-10	Kyowa Hakko Kogyo Co Ltd	医薬組成物
EP1524267A1 (en) *	2003-10-15	2005-04-20	Newron Pharmaceuticals S.p.A.	Substituted benzylaminoalkylene heterocycles
EP1588704A1 (en)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

2004
- 2004-04-22 EP EP04009532A patent/EP1588704A1/en not_active Withdrawn
2005
- 2005-04-19 EP EP07022078A patent/EP1900362B1/en not_active Expired - Lifetime
- 2005-04-19 US US11/578,988 patent/US8445513B2/en not_active Expired - Lifetime
- 2005-04-19 KR KR1020067021748A patent/KR101195819B1/ko not_active Expired - Lifetime
- 2005-04-19 EP EP05736365A patent/EP1737438B1/en not_active Expired - Lifetime
- 2005-04-19 ES ES05736365T patent/ES2313330T3/es not_active Expired - Lifetime
- 2005-04-19 ES ES07022078T patent/ES2357559T3/es not_active Expired - Lifetime
- 2005-04-19 DE DE602005009162T patent/DE602005009162D1/de not_active Expired - Lifetime
- 2005-04-19 SI SI200531224T patent/SI1900362T1/sl unknown
- 2005-04-19 PT PT05736365T patent/PT1737438E/pt unknown
- 2005-04-19 SI SI200530430T patent/SI1737438T1/sl unknown
- 2005-04-19 DK DK05736365T patent/DK1737438T3/da active
- 2005-04-19 RS RSP-2008/0531A patent/RS50667B/sr unknown
- 2005-04-19 JP JP2007508825A patent/JP5020069B2/ja not_active Expired - Lifetime
- 2005-04-19 AT AT07022078T patent/ATE494890T1/de active
- 2005-04-19 AU AU2005235428A patent/AU2005235428B2/en not_active Expired
- 2005-04-19 CN CN2005800118905A patent/CN1942179B/zh not_active Expired - Lifetime
- 2005-04-19 DE DE602005025941T patent/DE602005025941D1/de not_active Expired - Lifetime
- 2005-04-19 RU RU2006137079/15A patent/RU2403030C2/ru active
- 2005-04-19 AT AT05736365T patent/ATE405256T1/de active
- 2005-04-19 KR KR1020127003440A patent/KR101238377B1/ko not_active Expired - Lifetime
- 2005-04-19 ME MEP-2016-18A patent/ME02324B/me unknown
- 2005-04-19 DK DK07022078.5T patent/DK1900362T3/da active
- 2005-04-19 CA CA2563674A patent/CA2563674C/en not_active Expired - Lifetime
- 2005-04-19 WO PCT/EP2005/004166 patent/WO2005102300A1/en not_active Ceased
- 2005-04-19 PL PL07022078T patent/PL1900362T3/pl unknown
- 2005-04-19 PT PT07022078T patent/PT1900362E/pt unknown
- 2005-04-19 NZ NZ550664A patent/NZ550664A/en not_active IP Right Cessation
- 2005-04-19 BR BRPI0509976A patent/BRPI0509976B8/pt not_active IP Right Cessation
- 2005-04-19 PL PL05736365T patent/PL1737438T3/pl unknown
- 2005-04-19 MX MXPA06012163A patent/MXPA06012163A/es active IP Right Grant
- 2005-04-19 BR BR122020004541-8A patent/BR122020004541B1/pt active IP Right Grant
- 2005-04-19 ME MEP-2011-56A patent/ME01219B/me unknown
- 2005-04-19 RS RS20110128A patent/RS51791B/sr unknown
- 2005-04-19 HR HR20080593T patent/HRP20080593T3/xx unknown
2006
- 2006-10-19 NO NO20064732A patent/NO337900B1/no unknown
- 2006-10-19 IL IL178732A patent/IL178732A/en active IP Right Grant
2008
- 2008-11-10 CY CY20081101279T patent/CY1108494T1/el unknown
2011
- 2011-03-04 CY CY20111100255T patent/CY1111656T1/el unknown
- 2011-03-30 HR HR20110230T patent/HRP20110230T1/hr unknown
2013
- 2013-03-15 US US13/835,445 patent/US8697738B2/en not_active Expired - Lifetime
2015
- 2015-07-27 NO NO20150971A patent/NO338870B1/no unknown

Also Published As

Publication number	Publication date
DK1737438T3 (da)	2008-12-08
BRPI0509976B1 (pt)	2020-10-06
BRPI0509976B8 (pt)	2021-05-25
SI1900362T1 (sl)	2011-03-31
US20130217747A1 (en)	2013-08-22
HRP20110230T1 (hr)	2011-04-30
EP1737438A1 (en)	2007-01-03
RU2403030C2 (ru)	2010-11-10
EP1588704A1 (en)	2005-10-26
NO337900B1 (no)	2016-07-04
EP1900362A2 (en)	2008-03-19
IL178732A (en)	2013-01-31
DE602005009162D1 (de)	2008-10-02
ES2357559T3 (es)	2011-04-27
NO20064732L (no)	2006-11-22
BR122020004541B1 (pt)	2021-11-09
IL178732A0 (en)	2007-05-15
CN1942179B (zh)	2010-08-11
AU2005235428B2 (en)	2010-03-18
DE602005025941D1 (de)	2011-02-24
NO338870B1 (no)	2016-10-31
ES2313330T3 (es)	2009-03-01
KR20120028399A (ko)	2012-03-22
BRPI0509976A (pt)	2007-10-16
HK1099216A1 (en)	2007-08-10
KR101195819B1 (ko)	2012-11-05
AU2005235428A1 (en)	2005-11-03
ATE405256T1 (de)	2008-09-15
KR20070042914A (ko)	2007-04-24
CA2563674A1 (en)	2005-11-03
WO2005102300A1 (en)	2005-11-03
NO20150971L (no)	2006-11-22
KR101238377B1 (ko)	2013-03-04
CY1111656T1 (el)	2015-10-07
RU2006137079A (ru)	2008-04-27
PT1737438E (pt)	2008-12-22
CA2563674C (en)	2012-12-18
JP2007533691A (ja)	2007-11-22
JP5020069B2 (ja)	2012-09-05
ME01219B (me)	2013-06-20
PT1900362E (pt)	2011-03-09
CY1108494T1 (el)	2014-04-09
US20070203182A1 (en)	2007-08-30
NZ550664A (en)	2010-08-27
MXPA06012163A (es)	2007-01-17
RS50667B (sr)	2010-06-30
ATE494890T1 (de)	2011-01-15
EP1900362B1 (en)	2011-01-12
RS51791B (sr)	2011-12-31
US8697738B2 (en)	2014-04-15
SI1737438T1 (sl)	2008-12-31
EP1900362A3 (en)	2009-04-01
HRP20080593T3 (en)	2008-12-31
PL1737438T3 (pl)	2009-01-30
PL1900362T3 (pl)	2011-06-30
CN1942179A (zh)	2007-04-04
EP1737438B1 (en)	2008-08-20
ME02324B (me)	2016-06-20
US8445513B2 (en)	2013-05-21

Publication	Publication Date	Title
LTPA2021516I1 (da)	2021-08-10
NL301145I2 (nl)	2021-12-07	Tirbanibulin
PL1900362T3 (pl)	2011-06-30	Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
DK1730119T3 (da)	2008-08-11	Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
DK3567035T3 (da)	2022-09-05	N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
IL208607A0 (en)	2010-12-30	Improved nanobodiestm for the treatment of aggregation-mediated disorders
DK1708992T3 (da)	2007-11-05	Sulfonamidderivater til behandling af sygdomme
WO2010030891A3 (en)	2010-06-03	Aryl guanidine f1f0-atpase inhibitors and related methods
BRPI0407512A (pt)	2006-02-14	derivados de indolilmaleimida
BRPI0509660A (pt)	2007-10-09	compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
WO2008011113A3 (en)	2008-02-28	Thiadiazolidinone derivatives
NL1030418A1 (nl)	2006-05-16	Azabenzoxazolen voor de behandeling van CZS-stoornissen.
BRPI0821026A2 (pt)	2015-06-16	Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
ZA200607213B (en)	2008-04-30	Sulfonamide compounds for the treatment of neurodegenerative disorders
DK1907374T3 (da)	2012-10-15	Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater
PT2366393E (pt)	2013-10-04	Roflumilaste para o tratamento da hipertensão pulmonar
ITRM20050179A1 (it)	2006-10-14	Composizione impiegabile per il trattamento delle patologie paradontali.
IL185653A (en)	2013-04-30	Antibodies that call for the 1-kim salt region
FI20040180L (fi)	2005-08-07	Koostumus psoriasis-taudin hoitamiseksi
DK1940447T3 (da)	2014-01-20	Behandling af neurodegenrative lidelser
DK1961423T3 (da)	2012-06-25	Anvendelse af pneumocytter af type II ved behandling af lungesygdomme i forbindelse med lungefibrose
DK1909800T3 (da)	2011-08-01	Acylglycerophospholipider til behandling af symptomer i forbindelse med cancer
HUE036189T2 (hu)	2018-06-28	Monofenol, benzoldiol vagy szulfhidril vegyületek melanómák kezelésében való alkalmazásra
FR2871246B1 (fr)	2006-08-25	Lunettes
HK1119685A (en)	2009-03-13	Compounds for the treatment of inflammatory disorders